Parallel 37: Hepatitis C: Pre‐Approval Clinical Studies II

Günşar, Fulya; Turan, İlker; Ersöz, Galip; Karasu, Zeki; Özütemiz, Ömer; Lawitz, Eric; Poordad, Fred; H. Hyland, Robert; Liu, Lin; Dvory, Hadas; S. Pang, Phillip; M. Brainard, Diana; Gutiérrez, Julio; Guti- Errez, Julio; Y. Kwo, Paul; Bennett, Michael; Wang, Stanley; E. Vargas, Hugo; Wyles, David; Overcash, J; Ruane, Peter; Maliakkal, Benedict; Siddique, Asma; Raj Bhandari, Bal; Liu, Ran; Lin, Chih-Wei; I. Ng, Teresa; Mensa, Federico; Kort, Jens; Sia, Daniela; Harrington, Andrew; Zhang, Zhongyang; Campreciós, Genís; Toffanin, Sara; Moeini, Agrin; Isabel Fiel, M.; Hao, Ke; Higuera, Mónica; Miltiadous, Oriana; Cabellos, Laia; Cornellà, Helena; Hoshida, Yujin; Florman, Sander; Schwartz, Myron; M. Llovet, Josep; , N=30; , D; , E; , F; , G

doi:10.1002/hep.28207

Public

Parallel 37: Hepatitis C: Pre‐Approval Clinical Studies II

Shared by NobleBlocks on Oct 1, 2015 • 12:00 AM UTC

Authors:

Fulya Günşar

İlker Turan

Galip Ersöz

Abstract

Three hundred forty-one patients were on lamivudine, 60 were on adefovir, 188 were on entecavir, 467 were on tenofovir, and 32 were on combination therapies. ROC analysis for the predictive values of HCC scores showed that AUROC values were 0.804 for CU-HCC, 0.809 for REACH-B and 0.882 for GAG-HCC. ...

Subject

Medicine

Hepatitis C

Virology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!